AAO 2020: Alimera highlights NEW DAY Study for sustained-release intravitreal implant

November 15, 2020

By OT Staff Reports

Video

Rick Eiswirth, president and CEO of Alimera Sciences, provides an update on the company’s clinical trial that aims to evaluate its fluocinolone acetonide intravitreal implant 0.19 mg (Iluvien) as a baseline therapy for diabetic macular edema.

Rick Eiswirth, president and CEO of Alimera Sciences, provides an update on the company’s clinical trial that aims to evaluate its fluocinolone acetonide intravitreal implant 0.19 mg (Iluvien) as a baseline therapy for diabetic macular edema.

Newsletter

Keep your retina practice on the forefront—subscribe for expert analysis and emerging trends in retinal disease management.

Recent Videos

Carl Danzig, MD, director of vitreo-retinal services at the Rand Eye Institute in Deerfield Beach, Florida, shared an update on his research in OCS-01 drops for diabetic macular edema during ARVO

Jennifer Lim, MD, FARVO, FASRS, from the University of Illinois at Chicago, discussed her ARVO presentation on sickle cell retinopathy. She highlighted improvements in retinal surgery techniques and instrumentation.

At ARVO 2025, Christine Kay, MD, shares interim results from the PRISM trial population extension cohort

ARVO 2025: Rishi Singh, MD, discusses real-world clinical outcomes in patients with DME

Abby Markward and Hattie Hayes discuss the ASCRS Annual Meeting, the ASOA Annual Meeting, and the Retina Day event.

WIO 2024: An educator's perspective on shattering glass ceilings in ophthalmology

Hannah Chiu, MD, FRCSC, highlights some of the early benefits of an AI-operated telephone call system for postoperative patient care at WIO 2024

Terms and Conditions

Do Not Sell My Personal Information

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

© 2025 MJH Life Sciences

All rights reserved.